KODIAK SCIENCES INC. (KOD) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 200.60M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 51.09M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -246.42M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $200.60M | (m) | $51.09M | $-246.42M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $187.28M | (m) | $55.13M | $-235.09M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $182.37M | (m) | $58.86M | $-234.39M | $0.00 | (m) | (m) | (m) | Reported |
| 2025-09-30 | $168.65M | (m) | $54.20M | $-223.11M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $150.05M | (m) | $54.96M | $-207.39M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $139.81M | (m) | $57.70M | $-199.87M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $126.09M | (m) | $60.21M | $-186.85M | $0.00 | (m) | (m) | (m) | Reported |
| 2024-09-30 | $140.95M | (m) | $74.42M | $-204.04M | $0.00 | (m) | (m) | (m) | Reported |
| 2024-06-30 | $145.26M | (m) | $73.56M | $-211.91M | $5.00K | (m) | (m) | -42382.40× | Reported |
| 2024-03-31 | $179.71M | (m) | $80.98M | $-248.76M | $9.00K | (m) | (m) | -27640.11× | Reported |
| 2023-12-31 | $206.30M | (m) | $88.56M | $-277.32M | $13.00K | (m) | (m) | -21332.38× | Reported |
| 2023-09-30 | $215.66M | (m) | $91.50M | $-288.01M | $17.00K | (m) | (m) | -16941.94× | Reported |
| 2023-06-30 | $241.15M | (m) | $103.74M | $-312.99M | $16.00K | (m) | (m) | -19561.94× | Reported |
| 2023-03-31 | $247.93M | (m) | $103.92M | $-320.23M | $17.00K | (m) | (m) | -18836.88× | Reported |
| 2022-12-31 | $267.59M | (m) | $106.03M | $-341.38M | $18.00K | (m) | (m) | -18965.50× | Reported |
| 2022-09-30 | $287.19M | (m) | $53.00M | $-360.36M | $19.00K | (m) | (m) | -18966.42× | Reported |
| 2022-06-30 | $281.52M | (m) | $39.20M | $-348.42M | $21.00K | (m) | (m) | -16591.38× | Reported |
| 2022-03-31 | $253.18M | (m) | $24.31M | $-312.26M | $21.00K | (m) | (m) | -14869.52× | Reported |
| 2021-12-31 | $217.34M | (m) | $6.14M | $-267.05M | $22.00K | (m) | (m) | -12138.68× | Reported |
| 2021-09-30 | $179.10M | (m) | $42.84M | $-220.84M | $23.00K | (m) | (m) | -9601.91× | Reported |
| 2021-06-30 | $152.40M | (m) | $38.71M | $-189.97M | $23.00K | (m) | (m) | -8259.65× | Reported |
| 2021-03-31 | $127.56M | (m) | $34.51M | $-160.84M | $24.00K | (m) | (m) | -6701.75× | Reported |
| 2020-12-31 | $107.39M | (m) | $30.67M | $-136.01M | $25.00K | (m) | (m) | -5440.28× | Reported |
| 2020-09-30 | $82.86M | (m) | $23.15M | $-105.35M | $19.00K | (m) | (m) | -5544.68× | Reported |
| 2020-06-30 | $63.67M | (m) | $16.68M | $-81.42M | $15.00K | (m) | (m) | -5427.87× | Reported |
| 2020-03-31 | $51.95M | (m) | $11.04M | $-66.45M | $11.00K | (m) | (m) | -6041.18× | Reported |
| 2019-12-31 | $37.51M | (m) | $6.11M | $-49.19M | $8.00K | (m) | (m) | -6148.75× | Reported |
| 2019-09-30 | $31.53M | (m) | $5.29M | $-42.36M | $198.00K | (m) | (m) | -213.95× | Reported |
| 2019-06-30 | $26.12M | (m) | $4.32M | $-36.01M | $2.18M | (m) | (m) | -16.53× | Reported |
| 2019-03-31 | $20.87M | (m) | $3.73M | $-29.29M | $4.05M | (m) | (m) | -7.23× | Reported |
| 2018-12-31 | $18.79M | (m) | $2.67M | $-26.37M | $5.52M | (m) | (m) | -4.78× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | $-24.37M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | $-26.02M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $22.02M | (m) | $275.00K | $-25.52M | $1.19M | (m) | (m) | -21.54× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $14.05M | (m) | $272.00K | $-17.15M | $6.00K | (m) | (m) | -2858.50× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |